AI Portfolio Summary
In 2025 Q4, RTW INVESTMENTS, LP maintained a portfolio of 103 distinct positions. The most significant new addition to the portfolio was IRHYTHM TECHNOLOGIES, which now represents 2.10% of the total fund value. They heavily accumulated shares in INSMED INC, increasing their position by 57.0%. The fund also reduced its exposure to STRYKER CORPORATION by 50.0%.
Total Positions
103
Quarter
2025 Q4
Top Holding
MDGL (11.6%)
Top 10 Concentration
50.5%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 103
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MDGL
MADRIGAL PHARMA...
|
Healthcare | 11.63% | 11.27% |
#1
Prev: #1
|
7.0 | no change | no change |
P
S
|
1,993,687 | $1,161,003,688 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INSM
INSMED INC
|
Healthcare | 8.44% | 5.47% |
#2
3
Prev: #5
|
7.9 | 1,758,321 | 57.0% |
P
S
|
4,842,879 | $842,854,661 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTCT
PTC THERAPEUTIC...
|
Healthcare | 5.89% | 5.86% |
#3
1
Prev: #4
|
4.4 | no change | no change |
P
S
|
7,746,415 | $588,417,683 | 2016 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARGX
ARGENX SE
|
Healthcare | 5.67% | 6.12% |
#4
2
Prev: #2
|
3.8 | no change | no change |
P
S
|
673,497 | $566,377,302 | 2017 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 4.43% | 4.71% |
#5
1
Prev: #6
|
2.8 | -697,224 | -12.1% |
P
S
|
5,059,053 | $441,857,689 | 2019 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NTRA
NATERA INC
|
Healthcare | 3.44% | 3.97% |
#6
1
Prev: #7
|
1.4 | -500,000 | -25.0% |
P
S
|
1,500,000 | $343,635,000 | 2015 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RDNT
RADNET INC
|
Healthcare | 2.81% | 2.64% |
#7
4
Prev: #11
|
3.6 | 1,122,956 | 39.9% |
P
S
|
3,938,500 | $281,011,975 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 2.74% | 2.33% |
#8
5
Prev: #13
|
1.6 | 157,884 | 5.0% |
P
S
|
3,335,320 | $273,096,002 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 2.70% | 0.61% |
#9
31
Prev: #40
|
4.1 | 4,124,755 | 119.0% |
P
S
|
7,592,241 | $269,676,400 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PEN
PENUMBRA INC
|
Healthcare | 2.70% | 2.70% |
#10
Prev: #10
|
2.1 | no change | no change |
P
S
|
866,499 | $269,403,204 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRTC
IRHYTHM TECHNOL...
|
Healthcare | 2.10% | — |
#11
Prev: #—
|
4.3 | 1,181,990 | no change |
NEW
|
1,181,990 | $209,732,306 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 2.05% | 1.33% |
#12
9
Prev: #21
|
1.8 | no change | no change |
P
S
|
2,712,097 | $204,709,082 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APLS
APELLIS PHARMAC...
|
Healthcare | 1.93% | — |
#13
Prev: #—
|
4.3 | 7,666,764 | no change |
NEW
|
7,666,764 | $192,589,112 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACAD
ACADIA PHARMACE...
|
Healthcare | 1.91% | 1.88% |
#14
2
Prev: #16
|
1.8 | no change | no change |
P
S
|
7,144,524 | $190,830,236 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ESTA
ESTABLISHMENT L...
|
Healthcare | 1.89% | 1.31% |
#15
7
Prev: #22
|
1.8 | no change | no change |
P
S
|
2,588,831 | $188,674,003 | 2018 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
STOK
STOKE THERAPEUT...
|
Healthcare | 1.76% | 1.48% |
#16
4
Prev: #20
|
2.7 | 423,331 | 8.3% |
P
S
|
5,546,856 | $176,057,209 | 2019 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RGEN
REPLIGEN CORP
|
Healthcare | 1.75% | — |
#17
Prev: #—
|
4.2 | 1,064,000 | no change |
NEW
|
1,064,000 | $174,347,040 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 1.73% | 1.84% |
#18
1
Prev: #17
|
1.7 | no change | no change |
P
S
|
2,721,158 | $172,902,379 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMCR
IMMUNOCORE HLDG...
|
Healthcare | 1.69% | 2.18% |
#19
4
Prev: #15
|
1.7 | no change | no change |
P
S
|
4,869,798 | $169,030,689 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AXSM
AXSOME THERAPEU...
|
Healthcare | 1.62% | 1.67% |
#20
1
Prev: #19
|
0.6 | -230,882 | -20.6% |
P
S
|
888,001 | $162,184,503 | 2019 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GH
GUARDANT HEALTH...
|
Healthcare | 1.52% | 1.14% |
#21
4
Prev: #25
|
1.6 | no change | no change |
P
S
|
1,481,033 | $151,272,711 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NBIX
NEUROCRINE BIOS...
|
Healthcare | 1.51% | 1.84% |
#22
4
Prev: #18
|
1.6 | no change | no change |
P
S
|
1,062,072 | $150,633,672 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 1.37% | 0.75% |
#23
12
Prev: #35
|
2.5 | 550,000 | 15.2% |
P
S
|
4,171,996 | $136,674,589 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZLAB
ZAI LAB LTD
|
Healthcare | 1.23% | 0.96% |
#24
6
Prev: #30
|
3.5 | 4,667,660 | 203.7% |
P
S
|
6,959,032 | $122,757,324 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMTX
IMMATICS N.V
|
Healthcare | 1.20% | 0.93% |
#25
6
Prev: #31
|
3.0 | 2,617,737 | 29.7% |
P
S
|
11,433,354 | $120,050,217 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BLTE
BELITE BIO INC
|
Healthcare | 1.15% | 0.28% |
#26
27
Prev: #53
|
3.5 | 402,832 | 128.9% |
P
S
|
715,332 | $114,424,507 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
URGN
UROGEN PHARMA L...
|
Healthcare | 1.07% | 1.12% |
#27
1
Prev: #26
|
1.4 | no change | no change |
P
S
|
4,543,895 | $106,418,021 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XNCR
XENCOR INC
|
Healthcare | 1.04% | 0.90% |
#28
4
Prev: #32
|
2.4 | 556,407 | 8.9% |
P
S
|
6,777,461 | $103,762,928 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PODD
INSULET CORP
|
Healthcare | 0.92% | — |
#29
Prev: #—
|
3.9 | 324,600 | no change |
NEW
|
324,600 | $92,264,304 | 2017 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TSHA
TAYSHA GENE THE...
|
Healthcare | 0.90% | 0.98% |
#30
1
Prev: #29
|
0.4 | -7,955,994 | -32.7% |
P
S
|
16,398,297 | $90,190,634 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MASI
MASIMO CORP
|
Healthcare | 0.89% | 1.24% |
#31
8
Prev: #23
|
1.4 | no change | no change |
P
S
|
683,294 | $88,869,218 | 2015 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QURE
UNIQURE NV
|
Healthcare | 0.89% | 3.18% |
#32
23
Prev: #9
|
0.9 | -713,506 | -16.1% |
P
S
|
3,711,462 | $88,815,286 | 2017 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYK
STRYKER CORPORA...
|
Healthcare | 0.86% | 2.23% |
#33
19
Prev: #14
|
0.3 | -245,000 | -50.0% |
P
S
|
245,000 | $86,110,150 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 0.84% | 0.84% |
#34
1
Prev: #33
|
2.3 | 310,911 | 18.3% |
P
S
|
2,012,127 | $83,543,513 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CSTL
CASTLE BIOSCIEN...
|
Healthcare | 0.82% | — |
#35
Prev: #—
|
3.8 | 2,115,237 | no change |
NEW
|
2,115,237 | $82,282,719 | 2019 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 0.81% | — |
#36
Prev: #—
|
3.8 | 3,177,850 | no change |
NEW
|
3,177,850 | $80,780,947 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBNX
BETA BIONICS IN...
|
Healthcare | 0.76% | 0.81% |
#37
3
Prev: #34
|
0.3 | -799,191 | -24.2% |
P
S
|
2,500,000 | $76,175,000 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GHRS
GH RESEARCH PLC
|
Healthcare | 0.75% | 0.98% |
#38
10
Prev: #28
|
2.3 | 364,251 | 6.5% |
P
S
|
5,933,815 | $75,359,451 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
REPL
REPLIMUNE GROUP...
|
Healthcare | 0.70% | 0.33% |
#39
12
Prev: #51
|
2.3 | 744,620 | 11.6% |
P
S
|
7,140,352 | $69,404,221 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RARE
ULTRAGENYX PHAR...
|
Healthcare | 0.69% | 1.21% |
#40
16
Prev: #24
|
0.8 | -258,127 | -7.9% |
P
S
|
3,000,139 | $69,003,197 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRNX
CRINETICS PHARM...
|
Healthcare | 0.63% | 0.45% |
#41
6
Prev: #47
|
3.3 | 478,939 | 54.9% |
P
S
|
1,351,326 | $62,904,225 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 0.62% | 0.46% |
#42
3
Prev: #45
|
2.2 | 112,499 | 5.8% |
P
S
|
2,058,148 | $62,382,466 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RCKT
ROCKET PHARMACE...
|
Healthcare | 0.62% | 0.71% |
#43
7
Prev: #36
|
1.2 | no change | no change |
P
S
|
17,687,772 | $62,084,080 | 2018 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CMPS
COMPASS PATHWAY...
|
Healthcare | 0.61% | 0.61% |
#44
5
Prev: #39
|
0.7 | 50,000 | 0.6% |
P
S
|
8,757,390 | $60,425,991 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ISRG
INTUITIVE SURGI...
|
Healthcare | 0.57% | 1.12% |
#45
18
Prev: #27
|
0.2 | -101,228 | -50.0% |
P
S
|
101,228 | $57,331,490 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPT
RAPT THERAPEUTI...
|
Healthcare | 0.56% | 0.47% |
#46
2
Prev: #44
|
2.2 | 166,666 | 11.3% |
P
S
|
1,637,165 | $55,450,779 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CELC
CELCUITY INC
|
Healthcare | 0.55% | — |
#47
Prev: #—
|
3.7 | 550,160 | no change |
NEW
|
550,160 | $54,872,958 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VSTM
VERASTEM INC
|
Healthcare | 0.51% | 0.59% |
#48
7
Prev: #41
|
2.7 | 1,150,000 | 21.2% |
P
S
|
6,576,306 | $50,769,082 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 0.47% | 0.62% |
#49
11
Prev: #38
|
1.2 | no change | no change |
P
S
|
1,672,356 | $46,792,521 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 0.45% | 0.68% |
#50
13
Prev: #37
|
0.2 | -500,910 | -21.9% |
P
S
|
1,790,837 | $44,788,833 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 103 holdings